Gene Editing in Non-Small Cell Lung Cancer: Current Application and Future Perspective

Abstract

Lung cancer is the most common malignant tumor with the highest morbidity and mortality in the world, and non-small cell lung cancer (NSCLC) accounts for the vast majority of cases. At present, its main treatment methods are still traditional surgery, radiotherapy and chemotherapy, with disadvantages such as a high recurrence rate and limited effectiveness. Therefore, a new, better treatment method is urgently needed. Gene editing technology, as a new genetic engineering approach, has shown great potential in gene research, gene therapy and genetic improvement. It has also emerged as a promising treatment for lung cancer. This paper reviews the current research and applications of gene editing technology in NSCLC and other aspects of NSCLC, the therapeutic principle and mechanism of action, and the existing problems and prospects. This review aims to provide a basis for the prevention and treatment of NSCLC in the future and improve the survival rate of lung cancer patients.

Single‐cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation

“…These inhibitors are able to inhibit the proliferation of RB‐positive tumor cells by blocking the phosphorylation of RB proteins and effectively preventing the cell cycle from entering the G1 phase to the S phase 66 . In addition, CDK4/6 inhibitors inhibit tumor growth through a variety of mechanisms, including enhancement of cell arrest induced by signaling pathway inhibitors, modulation of cellular metabolism, promotion of anti‐tumor immune responses and induction of cellular senescence 68,69 . This demonstrates that CDK inhibitors can be a new therapeutic option for patients with LUAD in terms of modulating the cell cycle and enhancing the effects of signaling pathway inhibitors.…”

“…tors inhibit tumor growth through a variety of mechanisms, including enhancement of cell arrest induced by signaling pathway inhibitors, modulation of cellular metabolism, promotion of anti-tumor immune responses and induction of cellular senescence 68,69. This demonstrates that CDK inhibitors can be a new therapeutic option for patients with LUAD in terms of modulating the cell cycle and enhancing the effects of signaling pathway inhibitors.…”

SPC25 as a novel therapeutic and prognostic biomarker and its association with glycolysis, ferroptosis and ceRNA in lung adenocarcinoma

“…LUAD, as a highly malignant and heterogeneous disease with variable prognosis, leads to nearly two million deaths annually across the world [40]. Despite clinical treatment for LUAD patients has advanced in recent decades, their 5-year survival rate remains relatively low [41][42][43][44]. Therefore, it is imperative to develop a profound understanding of etiological factors and more efficient therapeutic approaches to understand the intricate progression within LUAD.…”

Applying machine learning algorithms to develop a survival prediction model for lung adenocarcinoma based on genes related to fatty acid metabolism

“…Lung cancer is one of the most deadly malignant tumors worldwide ( Wang et al, 2022b ). The metabolic reprogramming of cancer cells, particularly the modification of FAM, is firmly connected with tumor growth ( Maan et al, 2018 ).…”